You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205281 - 205290 of 207714 results
  1. PEROXYNITRATE NEUTRALIZING AGENTS FOR STROKE THERAPY

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION (provided by applicant):Nitric oxide (NO) and peroxynitrite are reactive, short-lived species that are important mediators of cellular injury in reperfusion injury associated with ischemic stroke. The applicants are developing novel classes of peroxynitrite neutrahzer compounds with protective effects in stroke. In this proposal, we present evidence that such agents are (1) inhibitors ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. ADENOSINE-3 AGONISTS FOR THE SUPPRESSION OF ARTHRITIS

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    Based on promising in vitro and in vivo data, the applicants are developing novel classes of compounds with anti-inflammatory effects, and with anti-arthritic potential. In this proposal, we present evidence that selected ligands of the adenosine-3 receptor are (1) inhibitors of the production of macrophage-derived pro-inflammatory mediators and enhancers of the production of anti-inflammatory med ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. ULTRAPOTENT PARS INHIBITOR FOR CNS TRAUMA

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): A recently discovered mechanism of cell injury, the "Poly (ADP-ribose) Synthetase (PARS) pathway" has been implicated in the pathogenesis of neuronal injury. Triggered by oxidant-induced DNA single strand breaks, PARS catalyzes an energy-consuming polymerization of ADP-ribose, resulting in NAD depletion, inhibition of glycolysis and mitochondrial respiration, ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. PARS inhibitor therapy for smoke inhalation

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Smoke inhalation is a major co-morbid factor in thermal injury. Therapy of smoke inhalation is supportive -there are no specific countermeasures to protect the lung from injury. We report the discovery that a nuclear cell death mechanism, mediated by poly (ADP-ribose) polymerase (PARP), accounts for the acute lung injury and inflammation in a classic ovine s ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  5. Novel antioxidants for periodontal disease

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION: (provided by the applicant) The current application represents the first revision of a Phase 2 continuation of the Phase I NIH SBIR Grant 1 R43 DE13625 entitled "A novel agent for the therapy of gingivitis". The applicants are leaders in the research and preclinical development of novel, nitric oxide based innovative technologies for the development of periodontal disease. In the Phas ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Development of ECG Software to Detect AMI

    SBC: INOVISE MEDICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to develop a computerized algorithm for the electrocardiogram (ECG) that will facilitate the reliable and early detection of acute myocardial infarction (AMI). The widely recognized value of thrombolytic therapy when delivered early in the management of patients with acute MI has made the development of such an algorithm especially important. Cur ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. N/A

    SBC: Insect Biotechnology, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  8. Noninvasive Devices for fMRI Studies in Drug Abuse-II

    SBC: INSIGHT NEUROIMAGING SYSTEMS, LLC            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  9. Monitoring of Heart Failure Patients via the Internet

    SBC: INSIGHT TELEHEALTH SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Heart failure constitutes the most frequent and expensive hospital discharge diagnosis in the United States, costing annually over $10 billion with over 900,000 hospital admissions. Care of patients with chronic heart failure is most efficient when patients have frequent communication with their providers, a full understanding of their illness and the abilit ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  10. N/A

    SBC: INSIGHTFUL CORPORATION            Topic: N/A

    N/A

    STTR Phase I 2000 Department of DefenseAir Force
US Flag An Official Website of the United States Government